(+/-)-3-[[1-(5-Benzyl-3-methyl-4-oxo-4,5-dihydro-isoxazolo[5,4-d]pyrimidin-6-yl)-propyl]-(2-methoxy-acetyl)-amino]-propionamide | 799295-42-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: (+/-)-3-[[1-(5-Benzyl-3-methyl-4-oxo-4,5-dihydro-isoxazolo[5,4-d]pyrimidin-6-yl)-propyl]-(2-methoxy-acetyl)-amino]-propionamide
• 英文别名: 3-[1-(5-Benzyl-3-methyl-4-oxo-[1,2]oxazolo[5,4-d]pyrimidin-6-yl)propyl-(2-methoxyacetyl)amino]propanamide
• CAS: 799295-42-4
• 化学式: C₂₂H₂₇N₅O₅
• 分子量: 441.487
• InChiKey: QCCVZYYLBVNDES-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  32
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  131
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• Bicyclicpyrimidones and their use to treat diseases
  申请人：——

  公开号：US20040242596A1

  公开（公告）日：2004-12-02

  The present invention is directed to dihydropyrimidones having formula I or II and methods of using them to induce mitotic arrest, thereby making them useful as anti-cancer agents and other diseases that can be treated by inducing mitotic arrest. 1

  本发明涉及具有化学式I或II的二氢嘧啶酮化合物，以及使用它们诱导有丝分裂停滞的方法，从而使它们可用作抗癌剂和其他可以通过诱导有丝分裂停滞来治疗的疾病。
• FUSED HETEROCYCLES AND USES THEREOF
  申请人：AstraZeneca AB

  公开号：EP1601673B1

  公开（公告）日：2009-06-10
• BICYCLICPYRIMIDONES AND THEIR USE TO TREAT DISEASES
  申请人：Bristol-Myers Squibb Company

  公开号：EP1628981A2

  公开（公告）日：2006-03-01
• US7022850B2
  申请人：——

  公开号：US7022850B2

  公开（公告）日：2006-04-04
• [EN] BICYCLICPYRIMIDONES AND THEIR USE TO TREAT DISEASES<br/>[FR] PYRIMIDONES BICYCLIQUES ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2004106492A2

  公开（公告）日：2004-12-09

  The present invention is directed to dihydropyrimidones having formula (I) or (II) and methods of using them to induce mitotic arrest, thereby making them useful as anti-cancer agents and other diseases that can be treated by inducing mitotic arrest.